Group 2A: HR+ Breast Cancer; Drug Resistance; Predictive Biomarkers

Wednesday, Dec 14
2:00 pm – 3:30 pm Eastern Time (US/New York)

Poster #P2-03-10

DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

Poster author Sarmistha Nanda will attend this session

Poster #P1-13-07:

Investigating NF1 mutations in circulating tumor DNA of patients with hormone-receptor positive (HR+) breast tumors resistant to CDK4/6 inhibition (CDK4/6i): A retrospective clinical analysis

Mentor: Kelly Shanahan, M.D.

In 2008, Kelly Shanahan had everything going for her: a busy and successful ob-gyn practice; a precocious 9-year- old daughter; and a well used passport from traveling all over the world with her family to attend conferences, with a liberal dose of vacation on the side. When she was diagnosed with stage IIB breast cancer in April, she considered it a mere bump in the road.

And for five years, breast cancer was an aside, something to put in the past medical history section of forms. Even when she developed sudden back pain, Kelly never thought it could be breast cancer rearing its ugly head – a pulled muscle, a herniated disc maybe, but not what it turned out to be: metastatic breast cancer in virtually every bone in her body, with a fractured vertebrae and an about to break left femur. Kelly was diagnosed on her 53rd birthday.

Neuropathy from the chemo did cost her her career, but she has found a new purpose in advocacy. Kelly is on the board of METAvivor, a member of the Metastatic Breast Cancer Alliance, a Komen Advocate in Science, a grant reviewer and research advocate. Kelly Shanahan is a mother, a wife, a daughter, a doctor, a woman LIVING with metastatic breast cancer.

Twitter: @stage4Kelly

Scientist: Rachel Schiff, Ph.D.

My research lab focuses on understanding the key signaling pathways in breast cancer and identifying therapeutic strategies to overcome them, particularly treatments targeting the estrogen receptor and the HER2 receptor. Major research themes include the crosstalk between the ER signaling network and growth factor and cellular kinase pathways, the role of ER co-regulators and pioneer factors in breast cancer development and metastasis, the identification of genomic and epigenomic alterations underlying resistance to endocrine and HER2-targeted therapies, and the development of biomarkers for effective and less toxic tailored therapeutic interventions.